medRxiv PreprintsInternational20 November 2026
Circulating gelsolin tracks disease stage in amyotrophic lateral sclerosis across four cohorts
This is an official announcement record
Firsthand records what medRxiv Preprints announced and links to the original. The wording below is theirs, not ours.
Amyotrophic lateral sclerosis is a fatal neurodegenerative disease with highly variable survival, and blood biomarkers beyond neurofilament light chain (NfL) are needed for prognosis and trial stratification. A biomarker of progress through an individualised disease course may be prognostic but independent of the rate of neurodegeneration. We analysed the serum proteome (5,401 proteins) and plasma and cerebrospinal fluid metabolomes (1,659 metabolites) of 94 patients with amyotrophic lateral sclerosis and 39 controls recruited in Sheffield, UK, and replicated findings in cohorts from Tel Aviv,
Read the official announcement
Opens www.medrxiv.org
More from medRxiv Preprints
- Unmet needs of Polish patients with cystic fibrosis seen through the lens of crowdfunding20 November 2026
- Motherly Plus: Study Protocol of a Randomized Controlled Trial Evaluating a Smartphone-Assisted Single-Session Psychotherapy Intervention for Postpartum Depression20 November 2026
- Targeting memory consolidation in major depression via pharmacological slow-wave sleep promotion20 November 2026
- Epidemiology of Cardiac Structure and Function Among African Caribbeans in Tobago: A Population-based Cohort Study20 November 2026
- Depressive Symptom Trajectories and Incident Cognitive Impairment by Outcome Ascertainment20 November 2026
This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.